循环胃癌细胞分离检测数据集

利用微流控芯片微过滤管道物理拦截及逐级捕获的方法，构建了基于微流控芯片的CTCs检测及分型微系统，建立了高灵敏、高特异性的CTCs检测、计数及鉴定新方法。采用自行研发的试剂盒，提高了CTCs的多靶标分型与识别有效性（可针对免疫治疗靶标PD-L1、上皮标志物EpCAM、间质标志物Vimentin及Her2等检测，用于指导后续的靶向用药及个体化治疗。实现了 CTCs富集、分型、识别与计数的自动化操作。研发的CTCs检测微系统获得医疗器械注册证（京经械备20200145号）。CTCs检测微系统临床验证结果：共收集683份临床血液标本，研究结果表明，这套检测体系可以在95%的病人外周血样本中检测到CTCs，CTCs与病人的分期、是否转移有密切的关系。A microfluidic chip-based circulating tumor cells (CTCs) detection and phenotyping microsystem was constructed through physical interception and stepwise capture in the microfiltration channels of the microfluidic chip, and a novel method with high sensitivity and high specificity for CTCs detection, counting and identification was established. Using the self-developed kit, the efficiency of multi-target phenotyping and identification of CTCs was enhanced; the kit is capable of detecting immunotherapeutic target PD-L1, epithelial marker EpCAM, mesenchymal marker Vimentin, Her2 and other relevant biomarkers, which can guide subsequent targeted therapy and personalized treatment. Automated operations for CTCs enrichment, phenotyping, identification and counting have been realized. The developed CTCs detection microsystem has obtained the medical device filing certificate with the designation No. 20200145, Beijing Economic-Technological Development Zone. Clinical validation of the CTCs detection microsystem was conducted using a total of 683 clinical blood specimens, and the results demonstrated that this detection system could detect CTCs in 95% of the peripheral blood samples from enrolled patients, with CTC levels closely correlated with the tumor stage and metastasis status of the patients.

搜集汇总

背景与挑战

背景概述

该数据集基于微流控芯片技术，实现了循环胃癌细胞（CTCs）的高灵敏检测与多靶标分型，已获医疗器械注册证。临床验证显示，其检测体系在95%的患者样本中有效检出CTCs，并与癌症分期和转移密切相关。